EUVIMEDEUVIMED entdecken
Crossref

Gender Differences in Lung Neuroendocrine Tumors: A Single-Center Experience

Alessia Liccardi, Annamaria Colao, Roberta Modica

Neuroendocrinology · 2024

DOI: 10.1159/000539412 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuroendocrinology, 2024. Verfasst von Alessia Liccardi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery; Endocrinology, Diabetology and Andrology Unit, Federico II University of Naples, Naples, Italy. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Lung Neoplasms, Sex Characteristics. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Gender difference may affect lung neuroendocrine tumor (L-NET) onset, progression, and outcomes as emerged in other cancers. This study aimed to analyze gender difference in L-NET to identify potential prognostic factors, to improve patient follow-up and therapeutic strategies.

Methods

Patients with histologically confirmed L-NEN diagnosis referred to the ENETS CoE of the Endocrinology Unit, Federico II University of Naples, from 2013 to 2023, were retrospectively evaluated.

Results

Among 48 patients with L-NEN, 38 (79.2%) with sporadic L-NET were enrolled: 22 typical (57.9%) and 16 atypical (42.1%) carcinoids, 22 (57.9%) female and 16 (42.1%) male, mean age at diagnosis 57.3 years (range 16–84). Median follow-up was 70.5 months (range 12–305). No statistical difference resulted regarding smoking habit, BMI, primary site (left/right and central/peripheral), and histological characteristics, between cohorts. Metastasis at diagnosis was found in 20 patients (52.3%), 10 female (10%) and 10 male (10%) (p: 0.20). Progressive disease (PD) was observed in 14 (36.8%) patients, and male sex developed PD more frequently 9/14 (64.3%) than female 5 (35.7%), p: 0.05. Male sex seemed to show more frequently bone metastasis without reaching statistical difference, 7 male/10 (70%), p: 0.06. Among 9 deaths (23.7%), 7 (77.8%) were men and 7 died for PD, p < 0.03. Male had a poorer prognosis than female regarding progression-free survival (PFS) (p: 0.04) and overall survival (p: 0.001), also when sub-groups of patient metastatic at diagnosis were compared (p: 0.02 and p: 0.02).

Conclusions

This study showed a worse prognosis in male than female with L-NET, despite similar clinical features, tumor type, stage, and treatment, with regard to PFS, OS, and metastatic spread. These findings may suggest a closer follow-up in men, with potential positive impact on outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsLung NeoplasmsSex CharacteristicsHumansMaleFemaleMiddle AgedAdultAgedAged, 80 and overAdolescentRetrospective StudiesYoung AdultPrognosisSex Factors

Stichwörter der Autor:innen

Atypical carcinoidGender differenceLung neuroendocrine tumorPrognostic factorTypical carcinoid

Autor:innen und Institutionen

  • Department of Clinical Medicine and Surgery; Endocrinology, Diabetology and Andrology Unit, Federico II University of Naples, Naples, Italy.
  • Department of Clinical Medicine and Surgery; Endocrinology, Diabetology and Andrology Unit, Federico II University of Naples, Naples, Italy, colao@unina.it.

Zitieren

APA

Liccardi, A., Colao, A., & Modica, R. (2024). Gender Differences in Lung Neuroendocrine Tumors: A Single-Center Experience. Neuroendocrinology. https://doi.org/10.1159/000539412

Vancouver

Liccardi A, Colao A, Modica R. Gender Differences in Lung Neuroendocrine Tumors: A Single-Center Experience. Neuroendocrinology. 2024. doi:10.1159/000539412

BibTeX
@article{Liccardi2024,
  author = {Liccardi, Alessia and Colao, Annamaria and Modica, Roberta},
  title = {Gender Differences in Lung Neuroendocrine Tumors: A Single-Center Experience},
  journal = {Neuroendocrinology},
  year = {2024},
  doi = {10.1159/000539412}
}
Kostenlos starten →